GO
Loading...

Eli Lilly and Co

More

  • SAN FRANCISCO, Jan 12- Eli Lilly and Co said on Monday that U.S. insurers are increasing pressure on the price of diabetes medications as they switch coverage from certain drugs to others to trim costs. "We've definitely seen increased price competition, more by payers than the companies themselves," Lilly Chief Financial Officer Derica Rice said on Monday in an...

  • 11 ways to play biotech Monday, 12 Jan 2015 | 6:59 PM ET

    Traders on CNBC's "Fast Money" outlined their strongest plays in the ever-volatile biotechnology space.

  • Your first trade for Monday Friday, 9 Jan 2015 | 5:56 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Early movers: COST, FDO, GOOG, HLF, GM & more Thursday, 8 Jan 2015 | 8:08 AM ET
    A trader works on the floor of the New York Stock Exchange in New York.

    Some of the names on the move ahead of the open.

  • Jan 7- Eli Lilly and Co, which has been battered in the past three years by competition from generics, forecast 2015 earnings and revenue just shy of Wall Street expectations. Lilly, which is betting on its rejuvenated pipeline of drugs, particularly for diabetes, oncology and animal health, forecast adjusted 2015 earnings of $3.10 to $3.20 per share.

  • Early movers: JCP, AXP, PEP, SNE, SIRI & more Wednesday, 7 Jan 2015 | 7:55 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Jan 7- Eli Lilly and Co, which has been battered in the past three years by competition from generics, forecast 2015 revenue shy of Wall Street expectations. The drugmaker expects sales of $20.3 billion to $20.8 billion for the year, it said on Wednesday. The company, which is betting on its rejuvenated pipeline of drugs particularly for diabetes, oncology and...

  • HALFTIME FINAL TRADES 1/6/15 Tuesday, 6 Jan 2015 | 2:35 PM ET
  • Early movers: CVEO, YHOO, NVS, GM, CLF & more Friday, 2 Jan 2015 | 7:45 AM ET
    NYSE exchange floor

    Some of the names on the move ahead of the open.

  • Lawyers cash in on favors from state prosecutors Friday, 19 Dec 2014 | 10:54 AM ET
    Gary King speaks during the Democratic Party for New Mexico 2014 Governor Forum in Albuquerque, N.M., May, 2014.

    The partnership is part of an industry pairing plaintiffs' lawyers with state attorneys general to sue companies. The NYT reports.

  • ZURICH, Dec 12- Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson& Johnson's Stelara. The data follows results last year showing Cosentyx, also known as secukinumab, was superior to Amgen's Embrel in a head-to-head study. Other drugmakers working on new...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • Mario Draghi is all over the place on ECB action Thursday, 4 Dec 2014 | 10:28 AM ET
    European Central Bank Governor Mario Draghi speaks at a news conference during the World Bank/IMF annual meetings in Washington, Oct. 11, 2014.

    European stocks weakened and the euro shot higher as the ECB chief implied any initiative to purchase sovereign debt isn't imminent.

  • Midday movers: Biogen Idec, Priceline, BP & more Tuesday, 2 Dec 2014 | 12:43 PM ET

    Some of Tuesday's midday movers

  • Dec 2- Biogen Idec Inc's research chief on Tuesday said the company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque levels and significantly improved cognition in a small early-stage study. Brain swelling has been a recurrent issue with experimental anti-amyloid Alzheimer's drugs,...

  • Biogen shares up; Alzheimer's drug shows promise Tuesday, 2 Dec 2014 | 9:46 AM ET

    Biogen Idec said its experimental medicine for Alzheimer's disease showed promise, prompting it to move "aggressively" into the most advanced stage of studies.

  • LONDON, Nov 13- AstraZeneca is developing an antibody treatment to reverse the blood-thinning effect of its heart drug Brilinta in rare emergency situations, such as urgent surgery or in the event of major bleeding. AstraZeneca said on Thursday the experimental antibody product, MEDI2452, was in pre-clinical tests at its MedImmune biotech unit.

  • Boehringer and Lilly will continue to jointly develop and market these drugs in 17 countries, including the United States, they said in a statement on Wednesday. A new insulin glargine product, which is approved in Europe, has won tentative approval in the United States. Sanofi SA said on Tuesday that growth in sales of its diabetes drugs would stall next year due...

  • Lilly, Boehringer revise terms of diabetes drugs alliance Wednesday, 29 Oct 2014 | 8:55 AM ET

    Oct 29- Eli Lilly and Co and German drugmaker Boehringer Ingelheim said they had revised the structure of their diabetes alliance for some countries. Under the alliance signed in 2011, the companies had agreed to develop and market diabetes drugs together. Boehringer and Eli Lilly said on Wednesday that they would continue joint development and marketing of...

  • Early Movers: DD, PFE, AET, TWTR, MSG, WMT & more Tuesday, 28 Oct 2014 | 8:07 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.